The aim of this project is to develop an original biomarker for Parkinson's disease (PD) and other parkinsonian syndromes (multiple system atrophy and progressive supranuclear palsy) based upon the detection of pathological alpha-synuclein species in routine colonoscopic biopsies.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
34
Usual procedure
Nantes University Hospital
Nantes, France
Presence of alpha-synuclein aggregates in colonic biopsies using immunohistochemistry
Colonic biopsies are obtained during the course of colonoscopy or rectosigmoidoscopy.
Time frame: 3 months
Presence of alpha-synuclein aggregates in colonic biopsies using 2D electrophoresis
Colonic biopsies are obtained during the course of colonoscopy or rectosigmoidoscopy.
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.